Access Erosion & Value Signals

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's stories are hitting right at the intersection of real-world evidence and system pressures.

MarcusSame here. We're looking at HCA's profit warning signaling broader access erosion; then subcutaneous Leqembi's approval with unchanged pricing; followed by the FTC-CVS insulin settlement; and ICER's expansion of early-phase scientific advice.

SaraThat second one is particularly telling — the budget impact question when administration improves but pricing doesn't shift is one the field hasn't fully worked out yet.

MarcusExactly. Let's get into it.

MarcusHCA Healthcare's profit warning is a red flag. They cited a 30% increase in bad debt and charity care, directly linked to 3.7 million more uninsured Americans since 2019. This isn't just a company-specific issue—it's a systemic access signal for innovative therapies.

SaraAbsolutely. What strikes me is how this compounds existing pressures. Unsurinsured populations mean fewer patients starting treatments, which affects both R&D returns and real-world evidence generation. The timing is critical as we face economic headwinds.

MarcusThat connects to something I keep coming back to: when safety nets erode, the entire value proposition for high-cost therapies gets destabilized. Especially in neurology and oncology where early intervention is key.

SaraI'd push back slightly on that framing though. The part that gives me pause is whether this is cyclical or structural. If it's structural, we're looking at fundamental HTA recalibration—not just temporary budget adjustments. The opportunity cost here is enormous.

MarcusFair point. The 3.7 million uninsured figure is staggering—it suggests the uninsured surge isn't an anomaly but a trend. That forces us to rethink how we demonstrate value in unstable coverage environments.

SaraExactly. And from the payer side, this means we're facing dual pressures: rising uncompensated care costs and shrinking revenue bases. It's a perfect storm for value assessments.

MarcusThe FDA's approval of subcutaneous Leqembi is clinically significant—reducing administration from 2.5 hours to 5 minutes. But the unchanged list price of $26,500 per year creates a value paradox.

SaraThat's one read—I'd frame it slightly differently. The time reduction is real, but for payers, the critical question is whether that translates to meaningful savings in healthcare resource utilization. If not, we're paying the same for marginal convenience gains.

MarcusWhat strikes me is how this reflects a broader tension in Alzheimer's pricing. The evidence base is strong, but the cost remains prohibitive for many systems. This formulation change doesn't address the core affordability issue.

SaraThe part that gives me pause is the precedent it sets. If manufacturers can maintain pricing for administration improvements without addressing cost-effectiveness, it risks normalizing incremental innovation at premium prices. That's problematic for sustainability.

MarcusThat's fair, though I think payers would see it differently—this could actually improve adherence and long-term outcomes if it reduces treatment burden. But the evidence isn't there yet to justify the price point.

SaraExactly. We need real-world data on whether the SC version actually increases treatment initiation and persistence. Without that, the value proposition remains theoretical.

MarcusThe FTC settlement with CVS Caremark over insulin pricing is significant—$100 million penalty and PBM practice changes. But the broader implications for drug pricing are murky.

SaraWhat strikes me is that while this targets insulin specifically, the anti-competitive practices in PBM fee structures are industry-wide. The question is whether this creates a domino effect or remains siloed to insulin.

MarcusThat connects to something I keep coming back to: PBM transparency is the real issue here. The settlement addresses symptoms but not the root cause of opaque pricing models that distort value assessment.

SaraI wonder if that's the full picture though. The FTC's focus on anti-competitive practices suggests they're viewing insulin as a special case due to its life-saving nature. That precedent could be limited in application to other therapeutic areas.

MarcusFair point. But the $100 million penalty sends a strong signal about enforcement priorities. It may encourage other PBMs to renegotiate practices proactively, which could indirectly benefit other drug categories.

SaraExactly. The operational impact on formulary negotiations could be substantial if PBMs reduce clawbacks and pass-through fees. That might actually improve net pricing for innovative therapies in the long run.

MarcusICER's expansion of scientific advice to pre-clinical and Phase I studies is a game-changer. They're explicitly aiming to embed HTA thinking from the earliest R&D stages.

SaraThat's one read—I'd frame it slightly differently. The real question is whether this creates more efficient pathways or just adds layers of complexity. Early-phase data is inherently noisy, and HTA bodies haven't historically valued it.

MarcusWhat strikes me is the timing. With increasing pressure on accelerated approvals, having HTA perspectives during Phase I could prevent later evidence gaps. It aligns with the FDA's push for more post-marketing requirements.

SaraThe part that gives me pause is resource allocation. If sponsors are now designing trials with HTA needs from day one, does that mean fewer resources for actual clinical development? There's an opportunity cost here.

MarcusThat's fair, though I think payers would see it differently—this could ultimately reduce the need for lengthy RWE generation post-launch. The key is whether it leads to more clinically relevant endpoints that matter to patients and systems.

SaraExactly. We'll need to see how ICER operationalizes this. If they can provide concrete guidance on trial design that improves real-world applicability, it could transform HEOR strategy fundamentally.

SaraA lot to think about today. I'll be watching how the HCA signal impacts payer coverage policies for high-cost therapies—especially in the upcoming Medicare Advantage Star Ratings.

MarcusSame — and for me the thread running through today is how operational changes in drug administration and PBM practices are reshaping value equations faster than evidence generation can adapt. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.